Identification of prognostic and therapeutic value of CC chemokines in urothelial bladder cancer: Evidence from comprehensive bioinformatic analysis
BMC Urology Dec 16, 2021
Li Y, Chen X, Li D, et al. - Analyzing the function of distinct CC chemokines in urothelial bladder cancer (BC), a significantly better prognosis of BC patients was observed in relation to high expression levels of CCL1, CCL2, CCL3, CCL4, CCL5, CCL8, CCL13, CCL15, CCL17, CCL18, CCL19, CCL22, CCL25, CCL27.
In this study, ONCOMINE, Gene Expression Profiling Interactive Analysis, Kaplan–Meier plotter, cBioPortal, GeneMANIA, and TIMER were utilized.
In BC patients, a significant decrease in transcriptional levels of CCL2/3/4/5/14/19/21/23 was evident.
Expression of CCL2/11/14/18/19/21/23/24/26 was significantly related to the pathological stage of BC patients.
Differentially expressed CC chemokines were shown to be primarily correlated with cytokine activity, chemokines receptor binding, chemotaxis, immune cell migration.
In addition, the expression of CC chemokines were significantly correlated with infiltration of various types of immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells).
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries